On Sept. 7, 2022, the U.S. Food and Drug Administration (FDA) announced it had approved Revance Therapeutics’ DAXXIFY (daxibotulinumtoxin A) for use in adults to temporarily improve the appearance of moderate to severe glabellar lines (wrinkles between the eyebrows).

The FDA approved DAXXIFY based on evidence from two clinical trials (Studies GL-1 and GL-2), of 609 adult patients with moderate to severe glabellar lines (wrinkles between the eyebrows). The trials were conducted at 30 sites in the United States and Canada.